Transchem

Transchem EBITDA Margin

The EBITDA Margin of Transchem (500422.BO) as of Nov 4, 2026 is -55.65 %. In the previous year, EBITDA Margin was -417.95 % — a change of -86.68% (higher).

EBITDA Margin

-55.65 %

YoY

-86.68%

Last updated:

EBITDA Margin of Transchem is 2025 -55.65 % . EBITDA Margin of Transchem was 2024 -417.95 % . It decreases by -86.68% higher compared to the previous year.

The Transchem EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2024
-417.95 INR
Jan 1, 2025
-55.65 INR
The Transchem EBITDA Margin history
YEAREBITDA MarginYoY
-55.65 %-86.68%
-417.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transchem Stock analysis

What does Transchem do? Transchem Ltd is a pharmaceutical company based in Thane, India, operating within the Health Care sector. The company has been publicly traded since its IPO on January 27, 1993, with a ticker symbol of 500422.BO and ISIN code INE019B01010. Its headquarters are located in Thane, Maharashtra. Transchem Ltd is engaged in the production and processing of pharmaceutical products, though specific product details are not provided. The company's website is https://www.transchem.net/. While the source description mentions the company's involvement in mushroom production, this appears to be an unverified or incorrect detail, as the company is classified under the Pharmaceuticals industry. The source also states that the company temporarily invests funds in short-term treasury operations while seeking new business opportunities, but this information should be treated with caution as it is not confirmed by official company sources. The company's primary focus remains on pharmaceutical manufacturing and processing within the Indian market. No additional details about its founding year, key personnel, acquisitions, or financial figures are provided in the available information. Transchem Ltd operates as a publicly listed entity on the Bombay Stock Exchange, though specific market capitalization or trading volume data is not included in the given facts. The company's activities are centered around pharmaceutical production, with no indication of other significant business lines beyond those related to the Health Care sector. Transchem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transchem stock

EBITDA Margin of Transchem is -55.65 % in 2025.

EBITDA Margin of Transchem changed from -417.95 % to -55.65 %, representing a -86.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Transchem since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Transchem with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Transchem

All Key Metrics — Transchem